{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:50:20Z","timestamp":1791597020375,"version":"4.3.4"},"reference-count":81,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100010881","name":"Suzhou Municipal Science and Technology Bureau","doi-asserted-by":"publisher","award":["SY202201"],"award-info":[{"award-number":["SY202201"]}],"id":[{"id":"10.13039\/501100010881","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["62371126"],"award-info":[{"award-number":["62371126"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA1205802"],"award-info":[{"award-number":["2022YFA1205802"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.isci.2026.117277","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:50:45Z","timestamp":1787586645000},"page":"117277","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["NF-\u03baB-driven immune checkpoint knockdown and cytokine expression in cancer cells for tumor immunotherapy"],"prefix":"10.1016","volume":"29","author":[{"given":"Yile","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ziyan","family":"Kong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yunqi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bing","family":"Pei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xueyuan","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weida","family":"Gong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rong","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meng","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3352-4690","authenticated-orcid":false,"given":"Jinke","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117277_bib1","first-page":"229","article-title":"Global cancer statistics 2022: Globocan estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.isci.2026.117277_bib2","first-page":"47","article-title":"Cancer incidence and mortality in China, 2022","volume":"4","author":"Han","year":"2024","journal-title":"J. Natl. Cancer Cent."},{"key":"10.1016\/j.isci.2026.117277_bib3","first-page":"12","article-title":"Cancer statistics, 2024","volume":"74","author":"Siegel","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.isci.2026.117277_bib4","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1158\/1541-7786.MCR-23-0411","article-title":"Updating the definition of cancer","volume":"21","author":"Brown","year":"2023","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.isci.2026.117277_bib5","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1016\/j.cell.2024.02.009","article-title":"Embracing cancer complexity: Hallmarks of systemic disease","volume":"187","author":"Swanton","year":"2024","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117277_bib6","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: Tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2026.117277_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1038\/s41392-022-01136-2","article-title":"Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response","volume":"7","author":"Wang","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.isci.2026.117277_bib8","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.trecan.2022.10.003","article-title":"The emerging field of oncolytic virus-based cancer immunotherapy","volume":"9","author":"Ma","year":"2023","journal-title":"Trends Cancer"},{"key":"10.1016\/j.isci.2026.117277_bib9","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1007\/s11523-020-00788-w","article-title":"Vaccine therapies for cancer: Then and now","volume":"16","author":"Michael","year":"2021","journal-title":"Target. Oncol."},{"key":"10.1016\/j.isci.2026.117277_bib10","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1038\/nbt1137","article-title":"Monoclonal antibody therapy of cancer","volume":"23","author":"Gregory","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.isci.2026.117277_bib11","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/d41573-024-00064-w","article-title":"The antibody-drug conjugate landscape","volume":"23","author":"Flynn","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2026.117277_bib12","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/s41571-021-00588-9","article-title":"Harnessing cytokines and chemokines for cancer therapy","volume":"19","author":"David","year":"2022","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117277_bib13","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1038\/s41416-023-02181-6","article-title":"Immune checkpoint inhibitor combinations-current and emerging strategies","volume":"128","author":"Robert","year":"2023","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.isci.2026.117277_bib14","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1126\/science.aaa4967","article-title":"Adoptive cell transfer as personalized immunotherapy for human cancer","volume":"348","author":"Rosenberg","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117277_bib15","article-title":"Adoptive T cell therapy for solid tumors: Current landscape and future challenges","volume":"15","author":"V\u00edctor","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117277_bib16","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1038\/s41375-023-01976-z","article-title":"Who wins the combat, CAR or TCR?","volume":"37","author":"Yun","year":"2023","journal-title":"Leukemia"},{"key":"10.1016\/j.isci.2026.117277_bib17","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1182\/blood-2017-06-741033","article-title":"CTLA-4: a moving target in immunotherapy","volume":"131","author":"Rowshanravan","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.isci.2026.117277_bib18","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1038\/s41551-019-0375-6","article-title":"Inhibiting PD-L1 palmitoylation enhances T-cell immune responses against tumours","volume":"3","author":"Yao","year":"2019","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.isci.2026.117277_bib19","doi-asserted-by":"crossref","DOI":"10.1080\/02656736.2022.2164625","article-title":"PD-1 monoclonal antibodies enhance the cryoablation-induced antitumor immune response: a breast cancer murine model research","volume":"40","author":"Yu","year":"2023","journal-title":"Int. J. Hyperther."},{"key":"10.1016\/j.isci.2026.117277_bib20","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1053\/j.gastro.2020.10.036","article-title":"PD-1 signaling promotes tumor-infiltrating myeloid-derived suppressor cells and gastric tumorigenesis in mice","volume":"160","author":"Kim","year":"2021","journal-title":"Gastroenterology"},{"key":"10.1016\/j.isci.2026.117277_bib21","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/j.immuni.2018.03.014","article-title":"Regulation and function of the PD-L1 checkpoint","volume":"48","author":"Sun","year":"2018","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.117277_bib22","doi-asserted-by":"crossref","first-page":"5023","DOI":"10.2147\/OTT.S105862","article-title":"PD-L1 expression in human cancers and its association with clinical outcomes","volume":"9","author":"Wang","year":"2016","journal-title":"OncoTargets Ther."},{"key":"10.1016\/j.isci.2026.117277_bib23","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.molcel.2019.09.030","article-title":"Mechanisms controlling PD-L1 expression in cancer","volume":"76","author":"Cha","year":"2019","journal-title":"Mol. Cell"},{"key":"10.1016\/j.isci.2026.117277_bib24","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1186\/s12885-024-12841-2","article-title":"Spartalizumab in combination with platinum-doublet chemotherapy with or without canakinumab in patients with PD-L1-unselected, metastatic NSCLC","volume":"24","author":"Santoro","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.isci.2026.117277_bib25","doi-asserted-by":"crossref","first-page":"1240","DOI":"10.1186\/s12903-024-05036-5","article-title":"Oral Lichenoid lesions induced by programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 bispecific antibody: a case report","volume":"24","author":"Jiang","year":"2024","journal-title":"BMC Oral Health"},{"key":"10.1016\/j.isci.2026.117277_bib26","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1111\/imr.13262","article-title":"Effects of immune-related adverse events (irAEs) and their treatment on antitumor immune responses","volume":"318","author":"Blum","year":"2023","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.isci.2026.117277_bib27","doi-asserted-by":"crossref","first-page":"ITC17","DOI":"10.7326\/AITC202402200","article-title":"Immune-related adverse events of immune checkpoint inhibitors","volume":"177","author":"Ramos-Casals","year":"2024","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/j.isci.2026.117277_bib28","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1002\/cncr.31043","article-title":"Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature","volume":"124","author":"Pillai","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.isci.2026.117277_bib29","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.1001\/jamaoncol.2019.0393","article-title":"Treatment-related adverse events of PD-1 and PD-L1 inhibitors in clinical trials: A systematic review and meta-analysis","volume":"5","author":"Wang","year":"2019","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.117277_bib30","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1186\/s12885-024-13105-9","article-title":"PD-1\/PD-L1 immune checkpoint inhibitors in the treatment of unresectable locally advanced or metastatic triple negative breast cancer: a meta-analysis on their efficacy and safety","volume":"24","author":"Wang","year":"2024","journal-title":"BMC Cancer"},{"key":"10.1016\/j.isci.2026.117277_bib31","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.adj9672","article-title":"Anti-PD-1 cancer immunotherapy induces central nervous system immune-related adverse events by microglia activation","volume":"16","author":"Vinnakota","year":"2024","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.117277_bib32","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s12022-024-09832-1","article-title":"Unravelling the reasons behind limited response to anti-PD therapy in ATC: A comprehensive evaluation of tumor-infiltrating immune cells and checkpoints","volume":"35","author":"Boruah","year":"2024","journal-title":"Endocr. Pathol."},{"key":"10.1016\/j.isci.2026.117277_bib33","doi-asserted-by":"crossref","first-page":"2790","DOI":"10.1016\/j.immuni.2024.10.014","article-title":"Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling","volume":"57","author":"Ogishi","year":"2024","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.117277_bib34","doi-asserted-by":"crossref","first-page":"10637","DOI":"10.1021\/acsnano.3c01733","article-title":"In situ sprayed nanovaccine suppressing exosomal PD-L1 by golgi apparatus disorganization for postsurgical melanoma immunotherapy","volume":"17","author":"Ye","year":"2023","journal-title":"ACS Nano"},{"key":"10.1016\/j.isci.2026.117277_bib35","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1186\/s12943-019-1074-3","article-title":"The role of exosomal PD-L1 in tumor progression and immunotherapy","volume":"18","author":"Xie","year":"2019","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.isci.2026.117277_bib36","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.trecan.2020.03.002","article-title":"Exosomal PD-L1: Roles in tumor progression and immunotherapy","volume":"6","author":"Morrissey","year":"2020","journal-title":"Trends Cancer"},{"key":"10.1016\/j.isci.2026.117277_bib37","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.coi.2012.01.010","article-title":"The CD47-SIRPalpha pathway in cancer immune evasion and potential therapeutic implications","volume":"24","author":"Chao","year":"2012","journal-title":"Curr. Opin. Immunol."},{"key":"10.1016\/j.isci.2026.117277_bib38","first-page":"37","article-title":"Insights into CD47\/SIRPalpha axis-targeting tumor immunotherapy","volume":"1","author":"Zhang","year":"2018","journal-title":"Antib. Ther."},{"key":"10.1016\/j.isci.2026.117277_bib39","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1200\/JCO.18.02018","article-title":"First-in-human, First-in-class phase I trial of the anti-CD47 antibody Hu5F9-G4 in patients with advanced cancers","volume":"37","author":"Sikic","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.isci.2026.117277_bib40","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.cell.2009.05.046","article-title":"CD47 is upregulated on circulating hematopoietic stem cells and leukemia cells to avoid phagocytosis","volume":"138","author":"Jaiswal","year":"2009","journal-title":"Cell"},{"key":"10.1016\/j.isci.2026.117277_bib41","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1038\/s41590-023-01671-2","article-title":"CD47 masks pro-phagocytic ligands in cis on tumor cells to suppress antitumor immunity","volume":"24","author":"Tang","year":"2023","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.isci.2026.117277_bib42","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jconrel.2023.09.041","article-title":"In situ hydrogel enhances non-efferocytic phagocytosis for post-surgical tumor treatment","volume":"363","author":"Lyu","year":"2023","journal-title":"J. Control. Release"},{"key":"10.1016\/j.isci.2026.117277_bib43","article-title":"Anti-CD47 treatment stimulates phagocytosis of glioblastoma by M1 and M2 polarized macrophages and promotes M1 polarized macrophages in vivo","volume":"11","author":"Zhang","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.117277_bib44","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202350824","article-title":"Proinflammatory polarization strongly reduces human macrophage in vitro phagocytosis of tumor cells in response to CD47 blockade","volume":"54","author":"Antonsen","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.isci.2026.117277_bib45","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200839","article-title":"The SIRPalpha-CD47 immune checkpoint in NK cells","volume":"218","author":"Deuse","year":"2021","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.isci.2026.117277_bib46","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.omto.2021.09.005","article-title":"CD47-targeted cancer immunogene therapy: Secreted SIRPalpha-Fc fusion protein eradicates tumors by macrophage and NK cell activation","volume":"23","author":"Billerhart","year":"2021","journal-title":"Mol. Ther. Oncolytics"},{"key":"10.1016\/j.isci.2026.117277_bib47","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2023.110255","article-title":"The CD47-SIRPalpha axis is a promising target for cancer immunotherapies","volume":"120","author":"Hao","year":"2023","journal-title":"Int. Immunopharmacol."},{"key":"10.1016\/j.isci.2026.117277_bib48","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1056\/NEJMoa1807315","article-title":"CD47 blockade by Hu5F9-G4 and Rituximab in non-Hodgkin's lymphoma","volume":"379","author":"Advani","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117277_bib49","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.jare.2023.10.009","article-title":"Deciphering the role of CD47 in cancer immunotherapy","volume":"63","author":"Liu","year":"2024","journal-title":"J. Adv. Res."},{"key":"10.1016\/j.isci.2026.117277_bib50","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1056\/NEJM198512053132327","article-title":"Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer","volume":"313","author":"Rosenberg","year":"1985","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117277_bib51","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.cytogfr.2016.06.001","article-title":"Interleukin 15: A key cytokine for immunotherapy","volume":"31","author":"Patidar","year":"2016","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.isci.2026.117277_bib52","doi-asserted-by":"crossref","first-page":"1747","DOI":"10.4049\/jimmunol.1400868","article-title":"Adipocyte IL-15 regulates local and systemic NK cell development","volume":"193","author":"Liou","year":"2014","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2026.117277_bib53","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1038\/s41573-022-00413-7","article-title":"Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders","volume":"21","author":"Maskalenko","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2026.117277_bib54","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.4049\/jimmunol.1500300","article-title":"IL-15 superagonist-mediated immunotoxicity: Role of NK cells and IFN-gamma","volume":"195","author":"Guo","year":"2015","journal-title":"J. Immunol."},{"key":"10.1016\/j.isci.2026.117277_bib55","article-title":"Next-generation anti-PD-L1\/IL-15 immunocytokine elicits superior antitumor immunity in cold tumors with minimal toxicity","volume":"5","author":"Shi","year":"2024","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.isci.2026.117277_bib56","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/j.cytogfr.2011.04.001","article-title":"Interleukin 15 as a promising candidate for tumor immunotherapy","volume":"22","author":"Jakobisiak","year":"2011","journal-title":"Cytokine Growth Factor Rev."},{"key":"10.1016\/j.isci.2026.117277_bib57","doi-asserted-by":"crossref","DOI":"10.1016\/j.cyto.2020.155258","article-title":"Interleukin-15 in autoimmunity","volume":"136","author":"Allard-Chamard","year":"2020","journal-title":"Cytokine"},{"key":"10.1016\/j.isci.2026.117277_bib58","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1038\/s41422-021-00543-4","article-title":"Tumor-conditional IL-15 pro-cytokine reactivates anti-tumor immunity with limited toxicity","volume":"31","author":"Guo","year":"2021","journal-title":"Cell Res."},{"key":"10.1016\/j.isci.2026.117277_bib59","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1089\/hum.2018.093","article-title":"A cell-specific nuclear factor-kappa B-activating gene expression strategy for delivering cancer immunotherapy","volume":"30","author":"Wang","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.isci.2026.117277_bib60","doi-asserted-by":"crossref","first-page":"3447","DOI":"10.2147\/JIR.S362732","article-title":"An AAV-based NF-kappaB-targeting gene therapy (rAAV-DMP-miR533) to inflammatory diseases","volume":"15","author":"Luo","year":"2022","journal-title":"J. Inflamm. Res."},{"key":"10.1016\/j.isci.2026.117277_bib61","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1186\/s12951-022-01663-8","article-title":"Ferroptosis assassinates tumor","volume":"20","author":"Luo","year":"2022","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.isci.2026.117277_bib62","doi-asserted-by":"crossref","first-page":"5311","DOI":"10.1038\/s41467-021-25632-1","article-title":"Gene interfered-ferroptosis therapy for cancers","volume":"12","author":"Gao","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117277_bib63","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1038\/s41417-024-00828-x","article-title":"NF-\u03baB-activated oncogene inhibition strategy for cancer gene therapy","volume":"31","author":"Dai","year":"2024","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.isci.2026.117277_bib64","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.11519","article-title":"Variation in the assessment of immune-related adverse event occurrence, grade, and timing in patients receiving immune checkpoint inhibitors","volume":"2","author":"Hsiehchen","year":"2019","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.isci.2026.117277_bib65","doi-asserted-by":"crossref","first-page":"293","DOI":"10.2147\/TCRM.S191022","article-title":"Risk and incidence of fatal adverse events associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"15","author":"Jiang","year":"2019","journal-title":"Therapeut. Clin. Risk Manag."},{"key":"10.1016\/j.isci.2026.117277_bib66","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: A systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.isci.2026.117277_bib67","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1007\/s40265-024-02060-1","article-title":"Nogapendekin alfa inbakicept: First approval","volume":"84","author":"Keam","year":"2024","journal-title":"Drugs"},{"key":"10.1016\/j.isci.2026.117277_bib68","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.70014","article-title":"Dual CD47 and PD-L1 blockade elicits anti-tumor immunity by intratumoral CD8(+) T cells","volume":"13","author":"Christo","year":"2024","journal-title":"Clin. Transl. Immunol."},{"key":"10.1016\/j.isci.2026.117277_bib69","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1038\/s41434-020-0128-x","article-title":"Cancer gene therapy by NF-kappaB-activated cancer cell-specific expression of CRISPR\/Cas9 targeting telomeres","volume":"27","author":"Dai","year":"2020","journal-title":"Gene Ther."},{"key":"10.1016\/j.isci.2026.117277_bib70","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s13045-024-01581-2","article-title":"Dual blockade immunotherapy targeting PD-1\/PD-L1 and CTLA-4 in lung cancer","volume":"17","author":"Cheng","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.isci.2026.117277_bib71","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1016\/j.ymthe.2023.10.015","article-title":"Lethal immunotoxicity in high-dose systemic AAV therapy","volume":"31","author":"Duan","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.117277_bib72","doi-asserted-by":"crossref","first-page":"704","DOI":"10.1089\/hum.2009.182","article-title":"Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors","volume":"21","author":"Boutin","year":"2010","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.isci.2026.117277_bib73","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.ymthe.2023.01.010","article-title":"Binding and neutralizing anti-AAV antibodies: Detection and implications for rAAV-mediated gene therapy","volume":"31","author":"Schulz","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.117277_bib74","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.ymthe.2024.06.007","article-title":"Chopping down antibodies for a good cause","volume":"32","author":"Biswas","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.117277_bib75","doi-asserted-by":"crossref","first-page":"1022","DOI":"10.1089\/hum.2022.216","article-title":"Neonatal Fc receptor inhibition enables adeno-associated virus gene therapy despite pre-existing humoral immunity","volume":"34","author":"Horiuchi","year":"2023","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/j.isci.2026.117277_bib76","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1038\/s41591-020-0911-7","article-title":"IgG-cleaving endopeptidase enables in vivo gene therapy in the presence of anti-AAV neutralizing antibodies","volume":"26","author":"Leborgne","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117277_bib77","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.139881","article-title":"Rescuing AAV gene transfer from neutralizing antibodies with an IgG-degrading enzyme","volume":"5","author":"Elmore","year":"2020","journal-title":"JCI Insight"},{"key":"10.1016\/j.isci.2026.117277_bib78","doi-asserted-by":"crossref","first-page":"2080","DOI":"10.1016\/j.ymthe.2024.05.004","article-title":"Engineered IgM and IgG cleaving enzymes for mitigating antibody neutralization and complement activation in AAV gene transfer","volume":"32","author":"Smith","year":"2024","journal-title":"Mol. Ther."},{"key":"10.1016\/j.isci.2026.117277_bib79","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1038\/d41573-024-00103-6","article-title":"Extracellular targeted protein degrader removes antibodies in first test in humans","volume":"23","author":"Mullard","year":"2024","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2026.117277_bib80","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2025-011759","article-title":"T cell-specific non-viral DNA delivery and in vivo CAR-T generation using targeted lipid nanoparticles","volume":"13","author":"Bimbo","year":"2025","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.isci.2026.117277_bib81","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202515480","article-title":"Targeting DNA-LNPs to endothelial cells improves expression magnitude, duration, and specificity","volume":"13","author":"Marzolini","year":"2026","journal-title":"Adv. Sci."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226026556?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226026556?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T01:10:54Z","timestamp":1791594654000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226026556"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":81,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S2589004226026556"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117277","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"NF-\u03baB-driven immune checkpoint knockdown and cytokine expression in cancer cells for tumor immunotherapy","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117277","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117277"}}